What Payers Want: Reliable Data
Executive Summary
Even as the federal government prepares to expand its comparative effectiveness research program due to Congressional impetus, private payers are sharpening their tools for evaluating drugs based on existing clinical trial data
You may also be interested in...
A Call For Action: Integrating Payor Requirements Into Phase III Clinical Trials
The biopharma industry is facing a paradigm shift in which pivotal trials, which traditionally address regulatory requirements, must also supply payors with clinically meaningful data - or the industry will continue to struggle with market access and disappointed expectations. Easton Associates foresees a two-step process emerging to address payors' needs.
A Call For Action: Integrating Payor Requirements Into Phase III Clinical Trials
The biopharma industry is facing a paradigm shift in which pivotal trials, which traditionally address regulatory requirements, must also supply payors with clinically meaningful data - or the industry will continue to struggle with market access and disappointed expectations. Easton Associates foresees a two-step process emerging to address payors' needs.